Janpix, Inc. Announces Appointment of Sanford (Sandy) Zweifach as Executive Chairman to its Board of Directors
December 12 2019 - 11:35AM
Janpix, Inc., a privately-held biopharmaceutical company dedicated
to the discovery and development of inhibitors/degraders of Signal
Transducer & Activator of Transcription (STAT) proteins for
oncological indications, announced today the appointment of Sanford
Zweifach as the Company’s Executive Chairman of the Board of
Directors.
Mr. Zweifach brings to Janpix almost 30 years of experience in
senior executive roles in the life sciences industry, with a focus
in corporate partnering, business development, operations, private
and public investing, and capital raising. Until recently, he was
the Co-Founder and CEO of Nuvelution Pharma, Inc. Previously
Mr. Zweifach was the Co-founder and CEO of Ascendancy Healthcare,
Inc. He has also held various other roles in the industry
including, Managing Director and CFO of Bay City Capital. He
currently serves as the Chair of Palladio Biosciences, Chair of
IMIDomics SL and Non-Executive Board Member of Compugen, Inc.
(NASDAQ: CGEN) and ESSA Pharm, Inc (NASDAQ: EPIX). He
received his BA in Biology from UC San Diego and an MS in Human
Physiology from UC Davis.
“I am very excited to welcome Sandy as the Executive Chairman of
our Board of Directors. He brings an exceptional combination
of operational, financing and deal experience to Janpix,” said
Roman Fleck, Ph.D., President and Chief Executive Officer of
Janpix. “His leadership and unique combination of skills will
be an incredibly valuable resource as we continue to build Janpix
into a leading drug development company dedicated to unlocking the
therapeutic potential of targeting STAT proteins.”
“I look forward to working together with Roman, Prof. Patrick
Gunning (scientific founder) and the entire Board of Janpix,” added
Mr. Zweifach. “Janpix’s STAT discovery platform has enormous
potential to address the large unmet medical needs of patients with
difficult cancers and I am delighted to assist in bringing together
the necessary elements to further develop and accelerate this
opportunity.”
About Janpix, Inc.:
Janpix, Inc. was launched in 2017 following seed financing by
medicxi. The Company’s aim is to advance the discovery and clinical
development of highly potent and selective STAT
inhibitors/degraders based on new structural insights and novel
chemistry. Using technologies and chemistry developed by Prof.
Patrick Gunning, the Canada Research Chair in Medicinal Chemistry
and a co-founder, Janpix has now been able to discover highly
potent and selective STAT3, STAT5, as well as pan-STAT3/5
inhibitors/degraders. In collaboration with leading academic labs
Janpix is advancing pre-clinical programs targeting different
hematological and solid tumors into the clinic. In particular,
Janpix is focused on hard-to-treat/resistant tumors for which there
are only limited treatment options. Janpix is based in Cambridge,
Mass.
For more information visit www.janpixbio.com
Contacts:Janpix, Inc.Roman FleckTel.:
+1-617-956-2803Email: roman@janpixbio.com
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Aug 2024 to Sep 2024
Compugen (NASDAQ:CGEN)
Historical Stock Chart
From Sep 2023 to Sep 2024